Cargando…

Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia

OBJECTIVE: To investigate serum neurofilament light chain (NfL) concentrations in frontotemporal dementia (FTD) and to see whether they are associated with the severity of disease. METHODS: Serum samples were collected from 74 participants (34 with behavioral variant FTD [bvFTD], 3 with FTD and moto...

Descripción completa

Detalles Bibliográficos
Autores principales: Rohrer, Jonathan D., Woollacott, Ione O.C., Dick, Katrina M., Brotherhood, Emilie, Gordon, Elizabeth, Fellows, Alexander, Toombs, Jamie, Druyeh, Ronald, Cardoso, M. Jorge, Ourselin, Sebastien, Nicholas, Jennifer M., Norgren, Niklas, Mead, Simon, Andreasson, Ulf, Blennow, Kaj, Schott, Jonathan M., Fox, Nick C., Warren, Jason D., Zetterberg, Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047041/
https://www.ncbi.nlm.nih.gov/pubmed/27581216
http://dx.doi.org/10.1212/WNL.0000000000003154
_version_ 1782457384008941568
author Rohrer, Jonathan D.
Woollacott, Ione O.C.
Dick, Katrina M.
Brotherhood, Emilie
Gordon, Elizabeth
Fellows, Alexander
Toombs, Jamie
Druyeh, Ronald
Cardoso, M. Jorge
Ourselin, Sebastien
Nicholas, Jennifer M.
Norgren, Niklas
Mead, Simon
Andreasson, Ulf
Blennow, Kaj
Schott, Jonathan M.
Fox, Nick C.
Warren, Jason D.
Zetterberg, Henrik
author_facet Rohrer, Jonathan D.
Woollacott, Ione O.C.
Dick, Katrina M.
Brotherhood, Emilie
Gordon, Elizabeth
Fellows, Alexander
Toombs, Jamie
Druyeh, Ronald
Cardoso, M. Jorge
Ourselin, Sebastien
Nicholas, Jennifer M.
Norgren, Niklas
Mead, Simon
Andreasson, Ulf
Blennow, Kaj
Schott, Jonathan M.
Fox, Nick C.
Warren, Jason D.
Zetterberg, Henrik
author_sort Rohrer, Jonathan D.
collection PubMed
description OBJECTIVE: To investigate serum neurofilament light chain (NfL) concentrations in frontotemporal dementia (FTD) and to see whether they are associated with the severity of disease. METHODS: Serum samples were collected from 74 participants (34 with behavioral variant FTD [bvFTD], 3 with FTD and motor neuron disease and 37 with primary progressive aphasia [PPA]) and 28 healthy controls. Twenty-four of the FTD participants carried a pathogenic mutation in C9orf72 (9), microtubule-associated protein tau (MAPT; 11), or progranulin (GRN; 4). Serum NfL concentrations were determined with the NF-Light kit transferred onto the single-molecule array platform and compared between FTD and healthy controls and between the FTD clinical and genetic subtypes. We also assessed the relationship between NfL concentrations and measures of cognition and brain volume. RESULTS: Serum NfL concentrations were higher in patients with FTD overall (mean 77.9 pg/mL [SD 51.3 pg/mL]) than controls (19.6 pg/mL [SD 8.2 pg/mL]; p < 0.001). Concentrations were also significantly higher in bvFTD (57.8 pg/mL [SD 33.1 pg/mL]) and both the semantic and nonfluent variants of PPA (95.9 and 82.5 pg/mL [SD 33.0 and 33.8 pg/mL], respectively) compared with controls and in semantic variant PPA compared with logopenic variant PPA. Concentrations were significantly higher than controls in both the C9orf72 and MAPT subgroups (79.2 and 40.5 pg/mL [SD 48.2 and 20.9 pg/mL], respectively) with a trend to a higher level in the GRN subgroup (138.5 pg/mL [SD 103.3 pg/mL). However, there was variability within all groups. Serum concentrations correlated particularly with frontal lobe atrophy rate (r = 0.53, p = 0.003). CONCLUSIONS: Increased serum NfL concentrations are seen in FTD but show wide variability within each clinical and genetic group. Higher concentrations may reflect the intensity of the disease in FTD and are associated with more rapid atrophy of the frontal lobes.
format Online
Article
Text
id pubmed-5047041
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-50470412016-10-13 Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia Rohrer, Jonathan D. Woollacott, Ione O.C. Dick, Katrina M. Brotherhood, Emilie Gordon, Elizabeth Fellows, Alexander Toombs, Jamie Druyeh, Ronald Cardoso, M. Jorge Ourselin, Sebastien Nicholas, Jennifer M. Norgren, Niklas Mead, Simon Andreasson, Ulf Blennow, Kaj Schott, Jonathan M. Fox, Nick C. Warren, Jason D. Zetterberg, Henrik Neurology Article OBJECTIVE: To investigate serum neurofilament light chain (NfL) concentrations in frontotemporal dementia (FTD) and to see whether they are associated with the severity of disease. METHODS: Serum samples were collected from 74 participants (34 with behavioral variant FTD [bvFTD], 3 with FTD and motor neuron disease and 37 with primary progressive aphasia [PPA]) and 28 healthy controls. Twenty-four of the FTD participants carried a pathogenic mutation in C9orf72 (9), microtubule-associated protein tau (MAPT; 11), or progranulin (GRN; 4). Serum NfL concentrations were determined with the NF-Light kit transferred onto the single-molecule array platform and compared between FTD and healthy controls and between the FTD clinical and genetic subtypes. We also assessed the relationship between NfL concentrations and measures of cognition and brain volume. RESULTS: Serum NfL concentrations were higher in patients with FTD overall (mean 77.9 pg/mL [SD 51.3 pg/mL]) than controls (19.6 pg/mL [SD 8.2 pg/mL]; p < 0.001). Concentrations were also significantly higher in bvFTD (57.8 pg/mL [SD 33.1 pg/mL]) and both the semantic and nonfluent variants of PPA (95.9 and 82.5 pg/mL [SD 33.0 and 33.8 pg/mL], respectively) compared with controls and in semantic variant PPA compared with logopenic variant PPA. Concentrations were significantly higher than controls in both the C9orf72 and MAPT subgroups (79.2 and 40.5 pg/mL [SD 48.2 and 20.9 pg/mL], respectively) with a trend to a higher level in the GRN subgroup (138.5 pg/mL [SD 103.3 pg/mL). However, there was variability within all groups. Serum concentrations correlated particularly with frontal lobe atrophy rate (r = 0.53, p = 0.003). CONCLUSIONS: Increased serum NfL concentrations are seen in FTD but show wide variability within each clinical and genetic group. Higher concentrations may reflect the intensity of the disease in FTD and are associated with more rapid atrophy of the frontal lobes. Lippincott Williams & Wilkins 2016-09-27 /pmc/articles/PMC5047041/ /pubmed/27581216 http://dx.doi.org/10.1212/WNL.0000000000003154 Text en © 2016 American Academy of Neurology https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Rohrer, Jonathan D.
Woollacott, Ione O.C.
Dick, Katrina M.
Brotherhood, Emilie
Gordon, Elizabeth
Fellows, Alexander
Toombs, Jamie
Druyeh, Ronald
Cardoso, M. Jorge
Ourselin, Sebastien
Nicholas, Jennifer M.
Norgren, Niklas
Mead, Simon
Andreasson, Ulf
Blennow, Kaj
Schott, Jonathan M.
Fox, Nick C.
Warren, Jason D.
Zetterberg, Henrik
Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
title Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
title_full Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
title_fullStr Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
title_full_unstemmed Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
title_short Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
title_sort serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5047041/
https://www.ncbi.nlm.nih.gov/pubmed/27581216
http://dx.doi.org/10.1212/WNL.0000000000003154
work_keys_str_mv AT rohrerjonathand serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia
AT woollacottioneoc serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia
AT dickkatrinam serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia
AT brotherhoodemilie serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia
AT gordonelizabeth serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia
AT fellowsalexander serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia
AT toombsjamie serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia
AT druyehronald serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia
AT cardosomjorge serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia
AT ourselinsebastien serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia
AT nicholasjenniferm serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia
AT norgrenniklas serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia
AT meadsimon serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia
AT andreassonulf serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia
AT blennowkaj serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia
AT schottjonathanm serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia
AT foxnickc serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia
AT warrenjasond serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia
AT zetterberghenrik serumneurofilamentlightchainproteinisameasureofdiseaseintensityinfrontotemporaldementia